These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29801704)

  • 1. Toward a Molecular Diagnosis in a Single Day for Patients With Advanced Non-small-cell Lung Cancer.
    Lambros L; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e537-e538. PubMed ID: 29801704
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular diagnostics in advanced NSCLC: trying to maximize a non-ideal situation.
    Lim EH; Tan P
    J Thorac Oncol; 2007 Aug; 2(8):782. PubMed ID: 17762350
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.
    VanderLaan PA; Chen Y; DiStasio M; Rangachari D; Costa DB; Heher YK
    Clin Lung Cancer; 2018 Sep; 19(5):e589-e590. PubMed ID: 29798809
    [No Abstract]   [Full Text] [Related]  

  • 4. Section IV: non-small cell lung cancer and malignant melanoma.
    Fisher KE; Pillai RN; Kudchadkar RR; Rossi MR
    Curr Probl Cancer; 2014; 38(5):180-98. PubMed ID: 25281457
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer.
    Trombino S; Neri M; Puntoni R; Angelini C; Loprevite M; Cesario A; Granone P; Imperatori A; Dominioni L; Ardizzoni A; Filiberti R; Russo P
    Clin Chem; 2005 Jul; 51(7):1313-4. PubMed ID: 15976131
    [No Abstract]   [Full Text] [Related]  

  • 6. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer.
    Rossi G; Papotti M; Barbareschi M; Graziano P; Pelosi G
    J Clin Oncol; 2009 Oct; 27(28):e141-2; author reply e143-4. PubMed ID: 19720885
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical implication of microrna for lung cancer.
    Wang Y; Zhang X; Liu L; Li H; Yu J; Wang C; Ren X
    Cancer Biother Radiopharm; 2013 May; 28(4):261-7. PubMed ID: 23496233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular markers for the diagnosis and prognosis of lung cancer.
    Gazdar AF
    Cancer; 1992 Mar; 69(6 Suppl):1592-9. PubMed ID: 1311627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of miRNA-26b in the diagnosis and prognosis of patients with non-small-cell lung cancer.
    Jiang LP; Zhu ZT; He CY
    Future Oncol; 2016 May; 12(9):1105-15. PubMed ID: 27033050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value.
    Deben C; Deschoolmeester V; Lardon F; Rolfo C; Pauwels P
    Crit Rev Oncol Hematol; 2016 Mar; 99():63-73. PubMed ID: 26689115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA and Lung Cancer.
    Del Vescovo V; Denti MA
    Adv Exp Med Biol; 2015; 889():153-77. PubMed ID: 26659001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.
    Planchard D; Remon J; Nowak F; Soria JC
    Am Soc Clin Oncol Educ Book; 2017; 37():12-17. PubMed ID: 28561640
    [No Abstract]   [Full Text] [Related]  

  • 14. Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
    Kim ES; Roy UB; Ersek JL; King J; Smith RA; Martin N; Martins R; Moore A; Silvestri GA; Jett J
    J Thorac Oncol; 2019 Mar; 14(3):338-342. PubMed ID: 30709747
    [No Abstract]   [Full Text] [Related]  

  • 15. Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer.
    Li W; Li N; Kang X; Shi K
    Clin Chim Acta; 2017 Dec; 475():152-156. PubMed ID: 29080690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.
    Yu XM; Wu YC; Liu X; Huang XC; Hou XX; Wang JL; Cheng XL; Mao WM; Ling ZQ
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
    Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
    Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.
    Garon EB; Abarca PA; Strunck JL; Nameth D; Neumann C; Wolf B; Kim KY; Marx C; Elashoff RM
    Crit Rev Oncog; 2015; 20(5-6):339-47. PubMed ID: 27279233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer.
    Wang RJ; Zheng YH; Wang P; Zhang JZ
    Int J Clin Exp Pathol; 2015; 8(1):765-71. PubMed ID: 25755772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and Prognostic Potential of Circulating Long Non-Coding RNAs in Non Small Cell Lung Cancer.
    Peng W; Wang J; Shan B; Peng Z; Dong Y; Shi W; He D; Cheng Y; Zhao W; Zhang C; Li B; Duan C
    Cell Physiol Biochem; 2018; 49(2):816-827. PubMed ID: 30165346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.